Benzinga | Oct 2, 2020 07:31AM EDT

Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk At The Liver Meeting 2020 Nov. 13-16

SOUTH SAN FRANCISCO,Calif., Oct. 2, 2020 /PRNewswire/ -- Akero Therapeutics,Inc.(NASDAQ:AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed torestore metabolic balance and improve the overall health of NASH patients, today announced that an abstract detailing additional analyses of the data from its Phase 2a BALANCED study of efruxifermin (EFX) has been accepted for presentation at The Liver Meeting Digital Experience(tm) 2020 of the American Association for the Study of Liver Diseases (AASLD) to be held November 13 - 16.

The new analyses will be presented in the presidential plenary oral session by Stephen Harrison, M.D., medical director of Pinnacle Clinical Research, in a presentation titled "Efruxifermin (EFX), a long-acting Fc-FGF21 fusion protein, administered for 16 weeks to patients with NASH substantially reduces liver fat and ALT, and improves liver histology: analysis of a randomized, placebo-controlled, Phase 2a study (BALANCED)." The abstract was published in the October supplement of Hepatology, the peer-reviewed journal of AASLD.

Abstract Title: Efruxifermin (EFX), a long-acting Fc-FGF21 fusion protein, administered for 16 weeks to patients with NASH substantially reduces liver fat and ALT, and improves liver histology: analysis of a randomized, placebo-controlled, Phase 2a study (BALANCED).

Abstract Number: 8

Presenting Author: Stephen Harrison, M.D.

Session Date: November 15, 2020

Session Time: 9-10:30 a.m. ET